BioLargo, Inc., a cleantech and life sciences innovator, today announced that its subsidiary, Clyra Medical Technologies, Inc. has entered into an exclusive distribution agreement with Al- Hikma FZCO, headquartered in Dubai, United Arab Emirates, to commercialize ViaCLYR™ across a broad territory spanning the Gulf Cooperation Council, the Levant, North Africa, and select adjacent markets.
ViaCLYR™ is Clyra's advanced wound irrigation solution, powered by its proprietary Clyrasept™ Copper-Iodine Complex Solution (CICS) technology - a broad-spectrum antimicrobial designed to be effective, biocompatible, and supportive of the body's natural healing processes.
The agreement reflects standard international distribution terms, including territory exclusivity tied to performance and the cooperation and protections customary in such contracts. Country-level regulatory work required for commercial sales across the territory has begun in key areas through a cooperative process between the parties.
"Al-Hikma, FZCO is exactly the kind of partner we wanted in this region - established, deeply networked across the Middle East and North Africa, and credible with regulators and the clinical community," said Steve Harrison, Chief Executive Officer of Clyra Medical Technologies.
Al-Hikma's portfolio strength in wound management "makes ViaCLYR™ a natural fit, and with regulatory work already in motion we are well positioned to build commercial momentum," Harrison says.
"This agreement meaningfully expands Clyra's international footprint and reflects our strategy of partnering with proven, well-established distributors," says Dennis P. Calvert, Chairman of Clyra Medical Technologies and CEO of BioLargo, Inc.
Al-Hikma FZCO serves a population of more than 500 million people across some of the most dynamic healthcare markets in the world, according to the companies.
"Clyra's copper-iodine technology is differentiated and aligned with our mission to bring innovative, high-quality healthcare products to the communities we serve," says Dr. Ali Farooq Abdul-Qader, Founder and Group CEO of Al- Hikma FZCO.
Al-Hikma FZCO is a specialized healthcare distribution and marketing group headquartered in Dubai, UAE. Founded in 2005 by Dr. Abdul-Qader, the company exports to approximately 25 countries, maintains more than 50 local distributor partnerships, employs around 500 people, and serves a population of more than 500 million across the Middle East, North Africa, and adjacent regions. Portfolio focus areas include conventional pharmaceuticals, wound management, medical devices, generics, food supplements, and OTC products. See www.alhikmaco.com.
BioLargo, Inc. (OTCQX:BLGO)
Copyright © 2026 California Business Journal. All Rights Reserved.
For California Business Journal Disclaimers, go to /terms-conditions/.
